Pharmaceutical - Johnson & Johnson, Patents


Current filters:

Johnson & JohnsonPatents

Popular Filters

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal


The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care…

EuropefentanylFinancialJohnson & JohnsonNeurologicalNovartisPatentsPharmaceuticalSandoz

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J


Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

EU Commission sends antitrust complaint to Johnson & Johnson and Novartis


The European Commission has informed US health care giant Johnson & Johnson (NYSE: JNJ) and Swiss drug…

DuragesicEuropefentanylGenericsJanssen-CilagJohnson & JohnsonLegalMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalSandoz

European Commission enforcement action in pharmaceutical sector following sector inquiry


Following its competition inquiry into the pharmaceutical sector of 2008/2009, the European Commission…

DuragesicEuropeGenericsJohnson & JohnsonLundbeckMarkets & MarketingPatentsPharmaceuticalServier

Affymax and Janssen Biotech enter $13 million peginesatide patent settlement


US biotech firm Affymax (Nasdaq: AFFY) says it has reached a global settlement agreement with Janssen…

AffymaxBiotechnologyJanssen PharmaceuticaJohnson & JohnsonOncologyPatentspeginesatidePharmaceuticalTakeda Pharmaceuticals

EU Commission opens antitrust proceedings against Johnson & Johnson and Novartis


The European Commission revealed last Friday that it has opened an antitrust investigation, on its own…

EuropefentanylGenericsJohnson & JohnsonLegalNeurologicalNovartisPatentsPharmaceutical

Back to top